Table 3.

Neuro-COVID Details

Neuro-COVID	n (%); mean (range)
New-onset symptoms	89/103 (86.4%)
Aggravated pre-existing symptoms	14/103 (13.6%)
Delay COVID-19/neurological symptoms	17 days (range: 0–166)
Onset before SARS-CoV-2 negative swab	70/103 (68%)
Onset after SARS-CoV-2 negative swab	33/103 (32%)
Onset delay after SARS-CoV-2 negative swab	14.2 days
Neurological examination	69 N; 34 P
Time (onset COVID-19-visit)	243.5 days (range: 22–618)
Time (onset Neuro-COVID-visit)	226.5 days (range: 20–617)
	Acute, n (%)	Persistent, n (%)
Fatigue	58/103 (56.3%)	49/58 (84.5%)
		49/103 (47.6%)
Olfactory/taste dysfunctions	58/103 (56.3%)	40/58 (69%)
		40/103 (38.9%)
Headache	47/103 (45.6%)	24/47 (51.1%)
		24/103 (38.8%)
Cognitive disorders	46/103 (44.7%)	42/46 (91.3%)
		42/103 (40.7%)
Sleep disorders	30/103 (29.1%)	25/30 (83.3%)
		25/103 (24.3%)
Sensitivity alterations	29/103 (28.2%)	27/29 (93.1%)
		27/103 (26.2%)
Dizziness	7/103 (6.8%)	3/7 (42.9%)
		3/103 (3%)
Treatment prescription	85/103 (82%)
Supplement prescription	67/103 (65%)
Specific drug prescription	35/103 (34%)
Follow-up	36/103 (35%)
Improvement	25/36 (69%)
Resolution	2/36 (5%)